Blog

  • Association of dietary diversity with disability in activities of daily living among older Chinese people: a longitudinal study | BMC Geriatrics

    Association of dietary diversity with disability in activities of daily living among older Chinese people: a longitudinal study | BMC Geriatrics

    Study population

    Data were obtained from the Chinese Longitudinal Healthy Longevity Surveys (CLHLS), a nationwide longitudinal survey with community-dwelling older adults in 23 provinces of China. Its primary purpose is to examine the determinants…

    Continue Reading

  • Upgrade to an Immersive Curved Gaming Monitor From Samsung for Under $200

    Upgrade to an Immersive Curved Gaming Monitor From Samsung for Under $200

    A regular monitor likely won’t cut it when it comes to PC gaming. Upgrading to a gaming monitor can offer deliver higher refresh rates and lower response times, among other bonuses that make it worth the change. But they can also be pricey, which…

    Continue Reading

  • Bad Fairies takes flight with Cynthia Erivo as the lead voice in upcoming animated musical

    We’re thrilled to share that Cynthia Erivo has been confirmed to star in Bad Fairies, the upcoming animated musical from Warner Bros. Pictures Animation and Locksmith Animation – with DNEG Animation serving as digital partner.

    The film stars…

    Continue Reading

  • Self-harming behaviors among forensic psychiatric patients living with intellectual disability | BMC Psychiatry

    Self-harming behaviors among forensic psychiatric patients living with intellectual disability | BMC Psychiatry

  • Ray I, Simpson AIF, Jones RM, Shatokhina K, Thakur A, Mulsant BH. Clinical, demographic, and criminal behaviour characteristics of patients with intellectual disabilities in a Canadian forensic program. Front Psychiatry. 2019;10:760.eCollection 2019. https://doi.org/10.3389/fpsyt.2019.00760.

  • Chester V, Völlm B, Tromans S, Kapugama C, Alexander RT. Long-stay patients with and without intellectual disability in forensic psychiatric settings: comparison of characteristics and needs. BJPsych Open. 2018;4(4):226–34.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kaggwa MM, Chaimowitz GA, Erb B, Prat S, Davids A, Moulden H, et al. Self-harming behaviors and forensic system-related factors: an analysis of the Ontario review board database. BMC Psychiatry. 2023;23(1):913.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Quinn S, Rhynas S, Gowland S, Cameron L, Braid N, S OC. Risk for intellectual disability populations in inpatient forensic settings in the united kingdom: A literature review. J Appl Res Intellect Disabil. 2022;35(6):1267–80.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Flygare Wallén E, Ljunggren G, Wahlström L, Pettersson D, Carlsson AC, Wändell P. The prevalence of self-harm and mental disorders among individuals with intellectual disabilities. Nord J Psychiatry. 2023;77(7):712–20.

    Article 
    PubMed 

    Google Scholar 

  • Duperouzel H, Fish R. Hurting no-one else’s body but your own: people with intellectual disability who self injure in a forensic service. J Appl Res Intellect Disabil. 2010;23(6):606–15.

    Article 

    Google Scholar 

  • Boylu ME, Taşdemir İ, Doğan M, Özcanlı T. Forensic psychiatric assessment in autism spectrum disorder: experience of a forensic psychiatry inpatient clinic from Türkiye. J Forensic Sci. 2024;69(6):2091–102.

    Article 
    PubMed 

    Google Scholar 

  • Boylu ME, Tasdemir I, Doğan M, Duran A. What is important in forensic psychiatric evaluation in people with down syndrome? A sample from Türkiye. J Intellect Disabil Offending Behav 2024;15.

  • Kaggwa MM, Chaimowitz GA, Erb B, Moulden H, Prat S, Davids A, Olagunju AT. Adverse childhood events and self-harming behaviours among individuals in Ontario forensic system: the mediating role of psychopathy. BMC Psychiatry. 2024;24(1):332.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Bogaerts S, Spreen M, Ter Horst P, Gerlsma C. Predictive validity of the HKT-R risk assessment tool: two and 5-year violent recidivism in a nationwide sample of Dutch forensic psychiatric patients. Int J Offender Ther Comp Criminol. 2018;62(8):2259–70.

    Article 
    PubMed 

    Google Scholar 

  • Ssekitto JM, Abaatyo J, Namatovu A, Akatusasira R, Kibet E, Kamau SG, et al. Filicide in Africa: a systematic review. BMC Public Health. 2024;24(1):2125.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kaggwa MM, Erb B, Prat S, Davids A, Bradford J, Chaimowitz GA, et al. Dual harm among patients in the Ontario forensic mental health system. PLoS ONE. 2025;19(12):e0316364.

    Article 

    Google Scholar 

  • Carr MJ, Steeg S, Mok PL, Pedersen CB, Antonsen S, Kapur N, et al. Adverse childhood experiences and risk of subsequently engaging in self-harm and violence towards other people—dual harm. Int J Environ Res Public Health. 2020;17(24):9409.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Martin J, Bureau J-F, Yurkowski K, Fournier TR, Lafontaine M-F, Cloutier P. Family-based risk factors for non-suicidal self-injury: considering influences of maltreatment, adverse family-life experiences, and parent–child relational risk. J Adolesc. 2016;49:170–80.

    Article 
    PubMed 

    Google Scholar 

  • McEvoy D, Brannigan R, Cooke L, Butler E, Walsh C, Arensman E, et al. Risk and protective factors for self-harm in adolescents and young adults: an umbrella review of systematic reviews. J Psychiatr Res. 2023. https://doi.org/10.1016/j.jpsychires.2023.10.017.

    Article 
    PubMed 

    Google Scholar 

  • Power J, Brown SL. Self-injurious behaviour: A review of the literature and implications for corrections. Correctional Service of Canada. 2010. https://www.canada.ca/en/correctional-service/corporate/library/research/report/216-full-report.html.

  • Marzano L, Fazel S, Rivlin A, Hawton K. Psychiatric disorders in women prisoners who have engaged in near-lethal self-harm: case–control study. Br J Psychiatry. 2010;197(3):219–26.

    Article 
    PubMed 

    Google Scholar 

  • Hawton K, Linsell L, Adeniji T, Sariaslan A, Fazel S. Self-harm in prisons in England and wales: an epidemiological study of prevalence, risk factors, clustering, and subsequent suicide. Lancet. 2014;383(9923):1147–54.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Favril L, Yu R, Hawton K, Fazel S. Risk factors for self-harm in prison: a systematic review and meta-analysis. Lancet Psychiatry. 2020;7(8):682–91.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Scott WP. Understanding the role of anger in self-harm: an interpretative phenomenological analysis. Doctoral thesis; City University London. 2006. https://openaccess.city.ac.uk/id/eprint/8490/.

    Google Scholar 

  • Laporte N, Klein Tuente S, Ozolins A, Westrin Å, Westling S, Wallinius M. Emotion regulation and self-harm among forensic psychiatric patients. Front Psychol. 2021. https://doi.org/10.3389/fpsyg.2021.710751.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Boylu ME, Görmez A, Turan Ş, Yeşilkaya ÜH, Boylu FB, Duran A. Offending and clinical characteristics of adults with autism spectrum disorder: experience at forensic psychiatry center in Türkiye between 2012 and 2022. Autism Res. 2025;18(1):110–21.

    Article 
    PubMed 

    Google Scholar 

  • Brown J, Beail N. Self-harm among people with intellectual disabilities living in secure service provision: a qualitative exploration. J Appl Res Intellect Disabil. 2009;22(6):503–13.

    Article 

    Google Scholar 

  • Fish RM. Working with people who harm themselves in a forensic learning disability service: experiences of direct care staff. J Learn Disabil. 2000;4(3):193–207.

    Article 

    Google Scholar 

  • Chaimowitz G, Moulden H, Upfold C, Mullally K, Mamak M. The Ontario forensic mental health system: a population-based review. Can J Psychiatry. 2022;67(6):481–9.

    Article 
    PubMed 

    Google Scholar 

  • Kaggwa MM, Davids A, Mohibi P, Erb B, Bradford J, Chaimowitz GA, et al. Weapon use during the index offense: a study among forensic psychiatry patients in Ontario, Canada. Inj Epidemiol. 2024;11(1):66.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Association WM. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.

    Article 

    Google Scholar 

  • Wechsler D. Wechsler Adult Intelligence Scale – Fourth Edition. (WAIS-IV) [Database record]. APA PsycTests. 2008.

  • Kaufman AS, Lichtenberger EO. Assessing adolescent and adult intelligence. 3rd ed. Hoboken, NJ, US: John Wiley & Sons Inc; 2006.

    Google Scholar 

  • Flinn LC, Hassett CL, Braham L. Development of forensic normative data for the WAIS-IV. J Forensic Pract. 2018;20(1):58–67.

    Article 

    Google Scholar 

  • Habets P, Jeandarme I, Uzieblo K, Oei K, Bogaerts S. Intelligence is in the eye of the beholder: investigating repeated IQ measurements in forensic psychiatry. J Appl Res Intellect Disabil. 2015;28(3):182–92.

    Article 
    PubMed 

    Google Scholar 

  • Iverson GL, Lange RT, Viljoen H, Brink J. WAIS-III general ability index in neuropsychiatry and forensic psychiatry inpatient samples ☆. Arch Clin Neuropsychol. 2006;21(1):77–82.

    Article 
    PubMed 

    Google Scholar 

  • Nazmie IF, Nebi MR, Zylfije Bekim H. Poor executive functioning associated with the risk of aggressive behavior recidivism in the forensic community in schizophrenic patients. Int J BioMed. 2013;3(2):94–9.

    Google Scholar 

  • de Keulen- Vos M, de Klerk A. Dutch forensic patients with and without intellectual disabilities: a comparison of demographic, offence, and diagnostic characteristics. Res Dev Disabil. 2022;126:104255.

    Article 

    Google Scholar 

  • Mitchell EH. The relationship between psychological response bias, neurocognitive performance validity, and estimates of IQ in criminal defendants. Doctoral dissertation, Rosalin Franklin University of Medicine and Science. 2014.

  • Sansone SM, Schneider A, Bickel E, Berry-Kravis E, Prescott C, Hessl D. Improving IQ measurement in intellectual disabilities using true deviation from population norms. J Neurodev Disord. 2014;6:1–15.

    Article 

    Google Scholar 

  • Kang H. Sample size determination and power analysis using the G*Power software. J Educ Eval Health Prof. 2021;18:17.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S. Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil. 2011;32(2):419–36.

    Article 
    PubMed 

    Google Scholar 

  • Bielska I, Ouellette-Kuntz H, Hunter D. Using national surveys for mental health surveillance of individuals with intellectual disabilities in Canada. Chron Dis Inj Can. 2012. https://doi.org/10.24095/hpcdp.32.4.03.

    Article 

    Google Scholar 

  • Matheson FI, Dastoori P, Whittingham L, Calzavara A, Keown LA, Durbin A, et al. Intellectual/developmental disabilities among people incarcerated in federal correctional facilities in Ontario, Canada: examining prevalence, health and correctional characteristics. J Appl Res Intellect Disabil. 2022;35(3):900–9.

    Article 
    PubMed 

    Google Scholar 

  • Gulati G, Kelly BD, Cusack A, Kilcommins S, Dunne CP. The experience of law enforcement officers interfacing with suspects who have an intellectual disability – a systematic review. Int J Law Psychiatry. 2020;72:101614.

    Article 
    PubMed 

    Google Scholar 

  • Nair R, Chen M, Dutt AS, Hagopian L, Singh A, Du M. Significant regional inequalities in the prevalence of intellectual disability and trends from 1990 to 2019: a systematic analysis of GBD 2019. Epidemiol Psychiatric Sci. 2022;31:e91.

    Article 
    CAS 

    Google Scholar 

  • Zhang T, Yin X, Chen H, Li Y, Chen J, Yang X. Global magnitude and temporal trends of idiopathic developmental intellectual disability attributable to lead exposure from 1990 to 2019: results from global burden of disease study. Sci Total Environ. 2022;834:155366.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Yang X, Liu C, Liu Y, He Z, Li J, Li Y, et al. The global burden, trends, and inequalities of individuals with developmental and intellectual disabilities attributable to iodine deficiency from 1990 to 2019 and its prediction up to 2030. Front Nutr. 2024. https://doi.org/10.3389/fnut.2024.1366525.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Mendez B, Bozzay M, Verona E. Internalizing and externalizing symptoms and aggression and violence in men and women. Aggress Behav. 2021;47(4):439–52.

    Article 
    PubMed 

    Google Scholar 

  • Sadeh N, Javdani S, Finy MS, Verona E. Gender differences in emotional risk for self-and other-directed violence among externalizing adults. J Consult Clin Psychol. 2011;79(1):106.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Brown SA, Williams K, Collins A. Past and recent deliberate self-harm: emotion and coping strategy differences. J Clin Psychol. 2007;63(9):791–803.

    Article 
    PubMed 

    Google Scholar 

  • Fliege H, Lee J-R, Grimm A, Klapp BF. Risk factors and correlates of deliberate self-harm behavior: a systematic review. J Psychosom Res. 2009;66(6):477–93.

    Article 
    PubMed 

    Google Scholar 

  • Favina A, Abaatyo J, Kaggwa MM. Dual harm among patients attending a mental health unit in Uganda: a hospital based retrospective study. BMC Psychiatry. 2024;24(1):154.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Plener PL, Schumacher TS, Munz LM, Groschwitz RC. The longitudinal course of non-suicidal self-injury and deliberate self-harm: a systematic review of the literature. Borderline Personal Disord Emot Dysregul. 2015;2:1–11.

    Google Scholar 

Continue Reading

  • mRNA tech offers hope for male infertility, restores sperm production

    mRNA tech offers hope for male infertility, restores sperm production

    A new mRNA approach successfully restored sperm production and led to the birth of viable offspring in a genetic mouse model. 

    The technique has been developed by the University of Osaka, Japan, in collaboration with Baylor College of…

    Continue Reading

  • World Athletics reveals 2025 Track Athlete of the Year nominees led by Jefferson-Wooden, McLaughlin-Levrone, Lyles, Wanyonyi — how to vote

    World Athletics reveals 2025 Track Athlete of the Year nominees led by Jefferson-Wooden, McLaughlin-Levrone, Lyles, Wanyonyi — how to vote

    How to vote for World Athletics Track Athlete of the Year 2025

    Fans can vote for their Women’s and Men’s Track Athlete of the Year on World Athletics’ social media pages, with each individual ‘like’ on Facebook or Instagram and each repost on…

    Continue Reading

  • Researchers use epoxidised cottonseed oil for textile finishes

    Researchers use epoxidised cottonseed oil for textile finishes

    A US research team has been exploring the use of epoxidised cottonseed oil (ECSO) in textile finishes. Image source: Adobe Stock

    A US research team has been exploring the use…

    Continue Reading

  • This experimental “super vaccine” stopped cancer cold in the lab

    This experimental “super vaccine” stopped cancer cold in the lab

    Researchers at the University of Massachusetts Amherst have shown that their nanoparticle-based vaccine can successfully prevent several aggressive cancers in mice, including melanoma, pancreatic cancer, and triple-negative breast cancer….

    Continue Reading

  • Real-World Study Shows Highest Treatment Adherence Rates With Zanubrutinib vs Other BTK Inhibitors in MCL

    Real-World Study Shows Highest Treatment Adherence Rates With Zanubrutinib vs Other BTK Inhibitors in MCL

    Patients with mantle cell lymphoma (MCL) treated with zanubrutinib (Brukinsa) in the community oncology setting achieved longer treatment durations, higher treatment adherence rates, and lower rates of treatment discontinuation compared with patients who received other BTK inhibitors, according to a real-world, retrospective, observational study of treatment patterns with BTK inhibitors, which was published in Future Oncology.1

    In total, 402 patients began treatment with ibrutinib (Imbruvica; n = 197; average follow-up, 746 days), acalabrutinib (Calquence; n = 161; average follow-up, 701 days) or zanubrutinib (n = 44; average follow-up, 493 days). Patients who received zanubrutinib had a significantly longer median duration of treatment, at 292 days, compared with those who received acalabrutinib (259 days) or ibrutinib (149 days; P < .01). Patients treated with zanubrutinib also displayed significantly better treatment adherence at more than 60, more than 90, more than 180, and more than 360 days compared with those who received acalabrutinib or zanubrutinib (P < .05). The rates of treatment adherence for more than 360 days in these respective cohorts were 53%, 45%, and 31%.

    Real-World Outcomes With BTK inhibitors in MCL: Key Takeaways

    • A real-world retrospective analysis found that patients with MCL treated with zanubrutinib had significantly longer median duration of treatment, higher treatment adherence, and the lowest rate of treatment discontinuation compared with those who received acalabrutinib or ibrutinib.
    • Although the study showed no significant differences in the incidence of clinical events between the cohorts during the 180-day follow-up period, patients in the zanubrutinib cohort had numerically lower rates of specific events like atrial fibrillation and fever compared with patients in the acalabrutinib and ibrutinib cohorts.
    • The results indicated strong outcomes for zanubrutinib in the post-BTK inhibitor setting, considering that 50% of the patients in the zanubrutinib group had a history of prior BTK inhibitor exposure before starting zanubrutinib treatment.

    Patients in the zanubrutinib cohort also had the lowest treatment discontinuation rate during follow-up, at 43.2% vs 45.2% in the ibrutinib cohort and 51.6% in the acalabrutinib cohort. The rates of treatment discontinuation due to toxicity in these respective cohorts were 13.6%, 13.2%, and 17.4%. The respective rates of treatment discontinuation due to nonresponse, disease progression, or worsened comorbidities were 18.2%, 24.9%, and 23.0%.

    “Overall, there were no significant differences between the BTK inhibitor cohorts in clinical events over the 180-day follow-up period,” lead study author Bijal Shah, MD, MS, and coauthors wrote in the paper. “However, the acalabrutinib and zanubrutinib cohorts generally had numerically lower rates of clinical events than the ibrutinib cohort. As the data mature, there could be an increase in time to next treatment and treatment duration for patients with MCL receiving zanubrutinib- or acalabrutinib-based treatment regimens.”

    Shah is an associate member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.

    What Are the Current Indications for BTK Inhibitors in MCL?

    In 2013, the FDA granted accelerated approval to ibrutinib for patients with MCL who had received at least 1 prior therapy.2 However, in 2023, this indication was voluntarily withdrawn by Johnson & Johnson and AbbVie citing insufficient data from the phase 3 SHINE confirmatory trial to support conversion to full approval.3 Furthermore,

    Furthermore, acalabrutinib is indicated in combination with bendamustine plus rituximab (Rituxan) for the treatment of adult patients with treatment-naive MCL who are ineligible for autologous stem cell transplant, as well as the treatment of adult patients with MCL who have received 1 or more prior lines of therapy.4 Additionally, zanubrutinib is approved for the treatment of adult patients who have received at least 1 prior therapy.5

    What Was the Design of the Real-World Retrospective Analysis of BTK Inhibitors in MCL?

    This retrospective analysis included electronic medical records from patients with MCL across 17 community oncology networks in the United States who began treatment with a BTK inhibitor between January 1, 2019, and November 30, 2021.1 Patients were followed for at least 6 months and examined for baseline characteristics and treatment outcomes.

    To be included in the study, patients were required to initiate a new BTK inhibitor–based regimen during the retrospective study index period and have at least 1 MCL diagnosis on the date of their first BTK inhibitor claim or during the pre-index period. Patients were excluded from the study if they were younger than 18 years of age at index, did not have a valid prescription or medical claim in the 3 months prior to the study index date, or did not have a valid prescription or medical claim in the 6 months following the study index date.

    Patients were stratified by the type of BTK inhibitor they initiated during the index period (acalabrutinib vs zanubrutinib vs ibrutinib). If patients began treatment with more than 1 BTK inhibitor–based regimen during this period, they were stratified based on a hierarchical approach.

    What Were the Baseline Characteristics of Patients Included in the Retrospective Analysis of BTK Inhibitors in MCL?

    Among all patients included in the study, 93% had received 1 or more systemic lines of therapy for MCL. In total, 50% of patients in the zanubrutinib group had a history of BTK inhibitor exposure prior to zanubrutinib; of these patients, 63.6% had received the previous BTK inhibitor within 60 days of initiating zanubrutinib.

    “The results of this analysis also show strong outcomes for zanubrutinib in the post-BTK inhibitor setting.”

    Additionally, 29.2% of patients in the acalabrutinib group had previously received another BTK inhibitor before acalabrutinib; 57.4% of these patients had received the prior BTK inhibitor within 60 days of initiating acalabrutinib. The study design required that no patients in the ibrutinib arm have a history of BTK inhibition prior to ibrutinib.

    At the start of study-specified BTK inhibitor therapy, the median ages of patients were similar between the zanubrutinib (75 years; range, 56-89), acalabrutinib (76 years; range, 36-89), and ibrutinib (72 years; range, 36-89) cohorts (P < .01). Furthermore, the percentages of patients who were at least 65 years of age were similar among the cohorts. Overall, investigators reported no significant differences across the cohorts regarding race, gender, ethnicity, or payer type.

    Regarding comorbidities, the incidence of chronic pulmonary disease during the pre-index period was significantly different between the zanubrutinib, acalabrutinib, and ibrutinib cohorts, at 25.0%, 16.8%, and 12.7%, respectively (P = .04). However, there were no significant differences among the cohorts regarding the prevalence of other prespecified comorbidities during the pre-index period, although patients in the zanubrutinib cohort had numerically highest rates of atrial fibrillation, cardiac arrhythmias, diabetes, gastroesophageal reflux disease, and renal disease. Conversely, patients in the acalabrutinib cohort had numerically the highest rates of cardiovascular disease and hypertension.

    What Additional Findings Were Seen in the Analysis of Real-World BTK Inhibitor Outcomes in MCL?

    During the 180-day follow-up period, no significant differences in the rates of clinical events between the cohorts were reported. Patients in the zanubrutinib cohort had the lowest rate of atrial fibrillation, at 9.1%, and no cases of atrial flutter were observed in this cohort. Additionally, the incidence of fever was lowest in the zanubrutinib arm, at 4.5% vs 12.4% in the acalabrutinib cohort and 16.8% in the ibrutinib cohort. Furthermore, the rates of myocardial infarction in these respective cohorts were 4.5%, 4.3%, and 7.6%.

    “Further analyses using more recent data and a longer time horizon are needed to validate these outcomes,” the authors concluded.

    References

    1. Shah BD, Xue M, Furnback W, Yang K. Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting. Future Oncol. 2025;21(23):3043-3049. doi:10.1080/14796694.2025.2554354
    2. Imbruvica (ibrutinib) capsules now approved in the US for mantle cell lymphoma patients who have received at least one prior therapy. News release. Janssen Biotech, Inc. November 13, 2013. Accessed October 10, 2025. https://www.jnj.com/media-center/press-releases/imbruvica-ibrutinib-capsules-now-approved-in-the-us-for-mantle-cell-lymphoma-patients-who-have-received-at-least-one-prior-therapy
    3. Update on Imbruvica (ibrutinib) US accelerated approvals for mantle cell lymphoma and marginal zone lymphoma indications. News release. AbbVie. April 6, 2023. Accessed October 10, 2025. https://www.jnj.com/media-center/press-releases/update-on-imbruvica-ibrutinib-u-s-accelerated-approvals-for-mantle-cell-lymphoma-and-marginal-zone-lymphoma-indications
    4. Calquence. Prescribing information. AstraZeneca; revised January 2025. Accessed October 10, 2025. https://drd9vrdh9yh09.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/e2a005a7-65a0-4388-a671-dc887815a938/e2a005a7-65a0-4388-a671-dc887815a938_viewable_rendition__v.pdf
    5. Brukinsa. Prescribing information. BeOne; revised June 2025. Accessed October 10, 2025. https://d1e94vsyskgtht.cloudfront.net/brukinsa/pdfs/brukinsa-prescribing-information.pdf

    Continue Reading

  • Pascal Wehrlein and Nico Müller to drive for Porsche in Formula E

    Pascal Wehrlein and Nico Müller to drive for Porsche in Formula E




    Pascal Wehrlein and Nico Müller will form the…

    Continue Reading